Sweet Ping Ng1,2, Richard Khor3,4, Mathias Bressel5, Michael MacManus1,4, John F Seymour6, Rodney J Hicks7,8, Andrew Wirth1,4. 1. Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. 2. Department of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas, USA. 3. Department of Radiation Oncology, Olivia Newton John Cancer Centre/ Austin Health, Melbourne, Victoria, Australia. 4. The Sir Peter MacCallum Department of Oncology, the University of Melbourne, Parkville, Victoria, Australia. 5. Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. 6. Department of Haematology, Peter MacCallum Cancer Centre, Royal Melbourne Hospital, University of Melbourne, Melbourne, Victoria, Australia. 7. The Sir Peter MacCallum Department of Oncology, the University of Melbourne, Parkville, Victoria, Australia. rod.hicks@petermac.org. 8. Centre for Molecular Imaging, Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, Victoria, 3000, Australia. rod.hicks@petermac.org.
Abstract
PURPOSE/OBJECTIVE(S): To evaluate the impact of positron emission tomography (PET) staging on overall survival (OS) and progression-free survival (PFS) in patients with early-stage (stages I and II) follicular lymphoma (ESFL) treated with radiation therapy alone. MATERIALS/ METHODS: Eighty-five patients with ESFL treated with curative-intent radiation therapy (RT) between December 2000 and May 2011 were identified. Of those, 13 who had no PET staging and 25 who received additional systemic therapy were excluded from the analysis. Thus, we analyzed 47 patients with PET-staged ESFL treated with definitive radiation therapy alone (dose > 23Gy). Tumour features, pre-treatment computed tomography (CT) and PET stage, dose fractionation, and radiation therapy field extent were recorded. The Kaplan-Meier method was used to estimate the OS and PFS. Patterns of failure were assessed as cumulative incidences assuming competing risks. RESULTS: Median age was 57 years (range 24-83); 43% were females. Most were PET stage 1 (76.6%). Median maximum nodal diameter was 3 cm. Median pre-treatment lactate dehydrogenase (LDH) was 327.5 (range 123-607, upper normal limit = 220). Twenty-six patients (55.3%) had infra-diaphragmatic disease. All received 30-36Gy in 15-24 fractions, with 59.6% treated with involved-field radiation therapy (IFRT) techniques. There was no significant difference in PFS between CT stage I and stage II (HR 1.30 95% CI [0.25-6.72], p = 0.75) with a 5-year PFS of 77% and 78% respectively. However, stage I on PET staging had a significantly better PFS than stage II (HR 4.66 95% CI [1.15-18.8], p = 0.038), with 5-year PFS of 84% and 60% respectively. Ten patients had recurrent disease, with distant disease being the first site of failure in seven patients. Seven-year OS was 91% (95% CI 79-100) for the whole cohort. CONCLUSION: FDG-PET should be considered an essential element in the evaluation of patients with ESFL being considered for RT.
PURPOSE/OBJECTIVE(S): To evaluate the impact of positron emission tomography (PET) staging on overall survival (OS) and progression-free survival (PFS) in patients with early-stage (stages I and II) follicular lymphoma (ESFL) treated with radiation therapy alone. MATERIALS/ METHODS: Eighty-five patients with ESFL treated with curative-intent radiation therapy (RT) between December 2000 and May 2011 were identified. Of those, 13 who had no PET staging and 25 who received additional systemic therapy were excluded from the analysis. Thus, we analyzed 47 patients with PET-staged ESFL treated with definitive radiation therapy alone (dose > 23Gy). Tumour features, pre-treatment computed tomography (CT) and PET stage, dose fractionation, and radiation therapy field extent were recorded. The Kaplan-Meier method was used to estimate the OS and PFS. Patterns of failure were assessed as cumulative incidences assuming competing risks. RESULTS: Median age was 57 years (range 24-83); 43% were females. Most were PET stage 1 (76.6%). Median maximum nodal diameter was 3 cm. Median pre-treatment lactate dehydrogenase (LDH) was 327.5 (range 123-607, upper normal limit = 220). Twenty-six patients (55.3%) had infra-diaphragmatic disease. All received 30-36Gy in 15-24 fractions, with 59.6% treated with involved-field radiation therapy (IFRT) techniques. There was no significant difference in PFS between CT stage I and stage II (HR 1.30 95% CI [0.25-6.72], p = 0.75) with a 5-year PFS of 77% and 78% respectively. However, stage I on PET staging had a significantly better PFS than stage II (HR 4.66 95% CI [1.15-18.8], p = 0.038), with 5-year PFS of 84% and 60% respectively. Ten patients had recurrent disease, with distant disease being the first site of failure in seven patients. Seven-year OS was 91% (95% CI 79-100) for the whole cohort. CONCLUSION: FDG-PET should be considered an essential element in the evaluation of patients with ESFL being considered for RT.
Authors: H Schöder; J Meta; C Yap; M Ariannejad; J Rao; M E Phelps; P E Valk; J Sayre; J Czernin Journal: J Nucl Med Date: 2001-08 Impact factor: 10.057
Authors: Robert Marcus; Kevin Imrie; Andrew Belch; David Cunningham; Eduardo Flores; John Catalano; Philippe Solal-Celigny; Fritz Offner; Jan Walewski; Joäo Raposo; Andrew Jack; Paul Smith Journal: Blood Date: 2004-10-19 Impact factor: 22.113
Authors: Andrew Wirth; Marcus Foo; John F Seymour; Michael P Macmanus; Rodney J Hicks Journal: Int J Radiat Oncol Biol Phys Date: 2008-03-04 Impact factor: 7.038
Authors: Jonathan W Friedberg; Michelle Byrtek; Brian K Link; Christopher Flowers; Michael Taylor; John Hainsworth; James R Cerhan; Andrew D Zelenetz; Jamie Hirata; Thomas P Miller Journal: J Clin Oncol Date: 2012-08-20 Impact factor: 44.544
Authors: Joshua W D Tobin; Gabrielle Rule; Katherine Colvin; Lourdes Calvente; David Hodgson; Stephen Bell; Chengetai Dunduru; James Gallo; Erica S Tsang; Xuan Tan; Jonathan Wong; Jessica Pearce; Robert Campbell; Shao Tneh; Sophie Shorten; Melissa Ng; Tara Cochrane; Constantine S Tam; Emad Abro; Eliza Hawkes; Georgina Hodges; Roopesh Kansara; Dipti Talaulikar; Michael Gilbertson; Anna M Johnston; Kerry J Savage; Diego Villa; Kirk Morris; Sumi Ratnasingam; Wojt Janowski; Robert Kridel; Chan Y Cheah; Michael MacManus; Nicholas Matigian; Peter Mollee; Maher K Gandhi; Greg Hapgood Journal: Blood Adv Date: 2019-10-08
Authors: Andrea C Lo; Lyndon P James; Anca Prica; Adam Raymakers; Stuart Peacock; Melody Qu; Alex V Louie; Kerry J Savage; Laurie H Sehn; David Hodgson; Joanna C Yang; Hans T T Eich; Andrew Wirth; M G Myriam Hunink Journal: J Nucl Med Date: 2021-08-19 Impact factor: 10.057
Authors: Imke E Karsten; Gabriele Reinartz; Michaela Pixberg; Kai Kröger; Michael Oertel; Birte Friedrichs; Georg Lenz; Hans Theodor Eich Journal: Biomedicines Date: 2021-05-17